Rare Cancers Australia founder and CEO Richard Vines sat down for a discussion with BioPharmaDispatch. He challenged the early direction of the health technology assessment review and called on health minister Mark Butler to set clear expectations for the process while saying it cannot be credibly conducted behind closed doors.
Richard Vines: A better designed spreadsheet is not going to help anybody
February 22, 2023 Latest NewsBioPharmaBioPharmaDispatch Executive
Latest Video
New Stories
-
Australia's 2026 flu vaccination season barely moves the needle on uptake
September 15, 2026 - - Latest News -
Persistent fatigue could be an overlooked sign of liver disease
September 15, 2026 - - Latest News -
Noxopharm moves lupus skin therapy toward next human trial
September 14, 2026 - - Australian Biotech -
Entropy's psychedelic infusion keeps binge eating disorder at bay three months after treatment ends
September 14, 2026 - - Latest News -
Diabetes and cancer blood tests reach WA and NT patients under new Healius deal
September 14, 2026 - - Australian Biotech -
FDA clears Telix's Pixclara as the world's first approved brain cancer imaging drug
September 14, 2026 - - Australian Biotech -
Scandal-hit KPMG still holds $37 million in health department work
September 14, 2026 - - Latest News
